Travere Therapeutics, Inc.

US$49.60As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:TVTXHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 10.14%
Div yield —
ROE (321.22%)
Biotechnology
Beta (5Y) 1.12
PE TTM —
TSR TTM 41.07%
Mkt cap US$4.761B
ROIC (12.77%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$49
(1.83%)
(71.15%)
Hold 0|6|10|1|1
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.52
0.50
0.54
0.52
5.87%
3.56%
13.77%
(0.91%)
Revenue$M
214.8
225.1
219.8
216.1
8.01%
12.07%
5.87%
6.19%
Peers (US$4.761B)
Cap (US$)
PE
4.534B
—
4.719B
—
Capital
TTM
5Y
10Y
Leveragex
4.344
2.642
1.840
EBIT/Intx
0.490
0.390
0.434
Own earn%
34.09
81.57
83.64
Sh yield%
38.50
26.48
25.17
Owners
Insiders/Inst%
7.36
26.45
Short interest%
1.05
SBC / revenue%
2.93
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
10
Op margin range%
20–29
$1 testx
0.0
Incr. ROIC%
2